[en] A clinical study with 100 patients with acute radiodermatitis is presented. They received treatment with Cryptomphalus Aspersa secretion (n=50) or its excipients (n=50) for three months. They were evaluated after first week, and at one, two, three and six months after initiation of therapy. In the group treated with Cryptomphalus Aspersa, a statistically significant clinical improvement in erythema, itching and burning pain was noted, both at first week and one month after starling therapy. These results open a new way in the future treatment of acute radiodermatitis. Cryptomphalus Aspersa is an alternative therapy for many patients diagnosed of malignant tumors which require radiotherapy, with specially good results in breast and neck radiodermatitis. (Author) 10 refs